计算溶液所需的质量、体积或浓度。
双组分纳米颗粒佐剂是基于QS-7组分与QS-21组分 (水溶性皂苷)的纳米佐剂系统,通过纳米笼状颗粒技术实现双佐剂协同递送,有效增强免疫反应和疫苗效应。采用纳米笼颗粒制备技术,颗粒粒径均一 (PDI < 0.2),粒径大小为40 nm。它呈无色透明状,是即用型溶液,可直接与抗原混合 (适用于冻干疫苗复溶)。
二、技术参数
|
.png)
图1 粒径示意图

图2 透射电镜照片
三、产品信息
1. 成分:采用南美皂皮树提取的QS-7组分 (纯度≥95%)和QS-21组分 (纯度≥98%)作为核心原料。所有原料符合EMA《佐剂质量指南》及WHO预认证 (PQ)要求。
2. 生产与检测:每项成分均经过检测,以确保符合严格的内部标准 (包括成分鉴定与批次一致性)。 该佐剂在GMP级超净车间通过严格控制的纳米笼状颗粒制备工艺 (批次一致性CV值<5%)生产而成。生产过程中采用0.22 μm除菌过滤确保无菌性,并通过加速试验 (25℃/75% RH,3个月)验证其稳定性,活性成分保留率>85%,粒径变化<10%。
3. 免疫应答:通过多通路协同激活免疫应答。其可促进CD4+ T细胞分化为Th1、Th2及T滤泡辅助细胞 (Tfh),并诱导CD8+记忆T细胞生成;同时通过上调共刺激分子和MHC分子,实现MHC II类途径的CD4+ T细胞激活与MHC I类交叉呈递的CD8+ T细胞活化。此外,双组分能触发NLRP3炎症体通路,释放IL-1β和IL-18等关键细胞因子,进一步强化免疫效应。
4. 安全性: 本产品具有以下风险:吞咽可能进入呼吸道 (致命危险);可能导致皮肤过敏反应;造成严重眼刺激。
5. 已验证应用场景:新冠疫苗;疟疾疫苗
6. 双组分纳米颗粒佐剂与不同抗原的推荐配伍比例
|
注:双组分纳米颗粒佐剂的浓度为100 μg/mL。
7. 推荐剂量
实验室动物各注射部位抗原/佐剂混合物的推荐注射量
|
The two-component nanoparticle adjuvant is a nano-adjuvant system based on QS-7 and QS-21 fractions (water-soluble saponins). It achieves synergistic delivery of dual adjuvants via nanocage particle technology, effectively enhancing immune responses and vaccine efficacy.Prepared using nanocage particle technology, the adjuvant features uniform particle size (PDI < 0.2) with a diameter of 40 nm. It appears as a colorless, transparent ready-to-use solution, which can be directly mixed with antigens (suitable for reconstitution of lyophilized vaccines).
II. Technical Parameters
|

Figure 1 Schematic diagram of particle size distributio
|

Figure 2 Transmission electron microscopy (TEM) image
III. Product Information
1. Components: Core raw materials are QS-7 fraction (purity ≥95%) and QS-21 fraction (purity ≥98%) extracted from Quillaja saponaria. All materials comply with EMA Guidelines on Adjuvant Quality and WHO Prequalification (PQ) requirements.
2. Manufacturing and Testing: Each component is tested to meet strict internal standards, including component identification and batch consistency.The adjuvant is manufactured in a GMP-grade cleanroom via a tightly controlled nanocage particle preparation process, with batch-to-batch consistency CV < 5%.Sterility is ensured by 0.22 μm sterile filtration during production. Stability is verified by accelerated testing (25 °C / 75% RH, 3 months), with active ingredient retention >85% and particle size variation <10%.
3. Immune ResponseThe adjuvant activates immune responses through multiple synergistic pathways.It promotes the differentiation of CD4⁺ T cells into Th1, Th2, and T follicular helper (Tfh) cells, and induces the generation of CD8⁺ memory T cells.By upregulating co-stimulatory molecules and MHC molecules, it activates CD4⁺ T cells via the MHC class II pathway and CD8⁺ T cells via MHC class I cross-presentation.In addition, the two components trigger the NLRP3 inflammasome pathway, releasing key cytokines such as IL-1β and IL-18 to further enhance immune effects.
4. Safety: This product presents the following hazards: If swallowed, it may enter the respiratory tract (fatal risk). May cause skin allergic reactions. Causes serious eye irritation.
5. Verified ApplicationsCOVID-19 vaccines; Malaria vaccines
6. Recommended Compatibility Ratios of Two-Component Nanoparticle Adjuvant with Different Antigens
|
Note: The concentration of the two-component nanoparticle adjuvant is 100 μg/mL.
7. Recommended Dosage
Recommended injection volume of antigen/adjuvant mixture at different administration sites in laboratory animals
|
| pH | 6.8-7.4 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | N1520829 |